# Multiple Myeloma Public Inventory v0

Stewarded by [frg.earth](https://frg.earth/).

- disease program: `multiple-myeloma`
- artifact id: `multiple-myeloma-public-inventory-v0`
- claim level: open-question
- inventory status: public v0 current-state map
- clinical boundary: research-use-only, not medical advice
- last reviewed: `2026-04-16`

## Purpose

This inventory summarizes what the public multiple myeloma lane contains now.
It is written for maintainers, contributors, researchers, advocates, and
builders who need the repo's current shape without private context.

It is not a scientific review, clinical review, patient guide, treatment
guide, trial guide, or cure claim.

## At A Glance

After the case-to-cure master completion audit is cataloged, the public
multiple myeloma surface contains 82 metadata-tracked artifacts:

| Class | Count | Meaning |
| --- | ---: | --- |
| dataset | 17 | Catalogs, public task queues, evidence-gap records, measurement context, issue indexes, response ledgers, outreach maps, source registry, and synthetic examples. |
| map | 8 | Cure-wedge, open research, concept, mechanism, immune-therapy boundary, post-BCMA frontier addendum, context-modifier, and case-to-cure stage maps. |
| protocol | 41 | Roadmaps, adaptive master plan, loop-governor handoff, gates, review plans, handoffs, checklists, endpoint and precursor guardrails, public contribution guidance, caregiver intake specification, caregiver projection gating, projection validator logic, consent/privacy/security/retention boundaries, static prototype planning, caregiver intake completion handoff, trial/therapy landscape non-advice gating, candidate hypothesis question scaffolding, multidisciplinary review packet builder routing, expert validation disposition-loop plumbing, case-to-public learning extraction gating, end-to-end synthetic route-table dry run, master completion audit, and review-packet protocols. |
| schema | 14 | Validated and contract-level shapes for disease maps, evidence claims, target records, therapy records, trial landscapes, open questions, case summaries, private intake boundaries, case-feature normalization, measurement normalization, therapy exposure timeline normalization, molecular and immune context normalization, evidence retrieval, and review-packet routing. |
| taxonomy | 1 | Multiple myeloma treatment-class vocabulary. |
| tool | 1 | Review-packet manifest route-table dry-run tool. |

## What Exists

| Area | Current Public Artifacts | Status |
| --- | --- | --- |
| Program navigation | [Public Roadmap v0](public-roadmap-v0.md), [Open Research Map v0.1](open-research-map-v0-1.md), [Public Loop Completion Handoff v0](public-loop-completion-handoff-v0.md), [Frontier Completion Audit Handoff v0](frontier-completion-audit-handoff-v0.md), [Public Review And Release Gate v0](public-review-release-gate-v0.md), this inventory, the release-gate pass, and the [Public Translation And Contribution Guide v0](public-translation-contribution-guide-v0.md). | Navigable public v0 surface. |
| Case-to-cure plumbing | [Case-To-Cure Adaptive Master Plan v0](case-to-cure-adaptive-master-plan-v0.md), [Case-To-Cure Loop Governor Handoff v0](case-to-cure-loop-governor-handoff-v0.md), [Private Intake Schema Contract v0](case-intake/private-intake-schema-contract-v0.md), [Static Synthetic Caregiver Prototype Plan v0](case-intake/static-synthetic-caregiver-prototype-plan-v0.md), [Caregiver Intake Public Projection Validator v0](case-intake/caregiver-intake-public-projection-validator-v0.md), [Consent Privacy Security Retention Gate v0](case-intake/consent-privacy-security-retention-gate-v0.md), [Case Feature Normalization Contract v0](case-feature-normalization-contract-v0.md), [Measurement Normalization Contract v0](measurements/measurement-normalization-contract-v0.md), [Therapy Exposure Timeline Contract v0](therapy-landscapes/therapy-exposure-timeline-contract-v0.md), [Molecular Immune Context Contract v0](contexts/molecular-immune-context-contract-v0.md), [Evidence Retrieval Packet v0](evidence-retrieval-packet-v0.md), [Trial Therapy Landscape Non-Advice Gate v0](therapy-landscapes/trial-therapy-landscape-non-advice-gate-v0.md), [Candidate Hypothesis Review Question Set v0](reviews/candidate-hypothesis-review-question-set-v0.md), [Multidisciplinary Review Packet Builder v0](reviews/multidisciplinary-review-packet-builder-v0.md), [Expert Validation Loop v0](reviews/expert-validation-loop-v0.md), [Case-To-Public Learning Extraction Gate v0](case-to-public-learning-extraction-gate-v0.md), [End-To-End Synthetic Case Dry Run v0](end-to-end-synthetic-case-dry-run-v0.md), [Case-To-Cure Master Completion Audit v0](case-to-cure-master-completion-audit-v0.md), [Case-To-Cure Pipeline Blueprint v0](case-to-cure-pipeline-blueprint-v0.md), [Case-To-Cure Stage Validator And Owner Map v0](case-to-cure-stage-validator-map-v0.md), [Caregiver Case Intake Product Spec v0](case-intake/caregiver-case-intake-product-spec-v0.md), [Caregiver Intake Public Projection Checklist v0](case-intake/caregiver-intake-public-projection-checklist-v0.md), [Case Intake Frontier Completion Audit Handoff v0](case-intake/case-intake-frontier-completion-audit-handoff-v0.md), [Synthetic Caregiver Intake v0](../../examples/multiple-myeloma-synthetic-caregiver-intake-v0.json), [Synthetic Case-To-Cure Pipeline v0](../../examples/multiple-myeloma-synthetic-case-to-cure-pipeline-v0.md), [Case-Feature Bundle Public Summary v0](../../schemas/case-feature-bundle-public-summary-v0.md), [Candidate-Option Scoring Rubric v0](candidate-option-scoring-rubric-v0.md), and [Publication-Gate Checklist v0](publication-gate-checklist-v0.md). | Public-safe shape only; the adaptive master plan now governs the durable next-step loop; the loop-governor handoff closes `case-to-cure-loop-governor-v0`, the private intake schema contract closes `private-intake-schema-contract-v0`, the static prototype plan closes `static-synthetic-caregiver-prototype-v0`, the projection validator closes `public-projection-validator-v0`, the consent/privacy/security/retention gate closes `consent-privacy-security-retention-gate-v0`, the case-feature normalization contract closes `case-feature-normalization-contract-v0`, the measurement normalization contract closes `measurement-normalization-contract-v0`, the therapy exposure timeline contract closes `therapy-exposure-timeline-contract-v0`, the molecular immune context contract closes `molecular-immune-context-contract-v0`, the evidence retrieval packet closes `evidence-retrieval-packet-v0`, the trial/therapy landscape non-advice gate closes `trial-therapy-landscape-non-advice-gate-v0`, the candidate hypothesis review question set closes `candidate-hypothesis-review-question-set-v0`, the multidisciplinary review packet builder closes `multidisciplinary-review-packet-builder-v0`, the expert validation loop closes `expert-validation-loop-v0`, the case-to-public learning extraction gate closes `case-to-public-learning-extraction-gate-v0`, the end-to-end synthetic case dry run closes `end-to-end-synthetic-case-dry-run-v0`, the master completion audit closes `case-to-cure-master-completion-audit-v0`, and ORP now blocks on `case-to-cure-public-scope-human-gate-blocker-v0`; every `case_00` through `case_14` stage has an owner artifact, validator or gate field, blocker, allowed public successor, and synthetic success/omit/refusal/blocker route; no remaining public-safe autonomous case-to-cure backlog item is ready without expert, private-lab, clinical, legal, regulatory, publication, or human-review gate clearance. |
| Evidence and gaps | [BCMA Antigen Escape Claim Set v0](evidence-claims/bcma-antigen-escape-claim-set-v0.md), [BCMA Antigen Escape Evidence Gap Register v0](evidence-gaps/bcma-antigen-escape-evidence-gap-register-v0.md), measurement audits, and public task queues. | Source-backed and limitation-heavy; expert review still needed. |
| Measurement language | [MRD And Relapse Measurement Glossary v0](measurements/mrd-and-relapse-measurement-glossary-v0.md), [MRD Endpoint Language Guardrail Addendum v0](measurements/mrd-endpoint-language-guardrail-addendum-v0.md), [Measurement Normalization Contract v0](measurements/measurement-normalization-contract-v0.md), and [BCMA Measurement Context Audit v0](measurements/bcma-measurement-context-audit-v0.md). | MRD, response-depth, relapse, labs, imaging, and endpoint language must preserve method, sample, threshold, timepoint, durability, endpoint role, source context, uncertainty, and limitations before reuse. |
| Immune therapy landscape | [Immune Therapy Sequencing And Access Boundary v0](therapy-landscapes/immune-therapy-sequencing-access-boundary-v0.md), [Therapy Exposure Timeline Contract v0](therapy-landscapes/therapy-exposure-timeline-contract-v0.md), [Trial Therapy Landscape Non-Advice Gate v0](therapy-landscapes/trial-therapy-landscape-non-advice-gate-v0.md), [Treatment-Class Taxonomy v0](../../taxonomies/multiple-myeloma-treatment-class-taxonomy-v0.md), and therapy-record schema/template artifacts. | CAR T, bispecific, antibody-drug conjugate, and adjacent-target references require source IDs, status date, jurisdiction, exposure context, source freshness, access-date state, uncertainty, and no-availability/no-eligibility/no-matching/no-ranking boundaries before reuse. |
| Mechanism work | [Post-CAR T Relapse Mechanism Map v0](mechanisms/post-car-t-relapse-mechanism-map-v0.md), [Post-BCMA Resistance Frontier Addendum v0](mechanisms/post-bcma-resistance-frontier-addendum-v0.md), extraction guide, extraction records, and coverage report. | Navigation and claim-level coverage only; counts and mechanism families are not evidence-strength rankings or patient-option guidance. |
| Precursor and interception boundaries | [Precursor, Risk, And Interception Boundary Note v0](precursors/precursor-risk-interception-boundary-note-v0.md). | MGUS, smoldering myeloma, risk, early-intervention, and prevention-adjacent language is source-context-only and cannot become screening, personal-risk, treatment, trial, monitoring, or prevention advice. |
| Context modifiers | [High-Risk, Extramedullary, Organ, And Frailty Context Modifier Map v0](contexts/high-risk-organ-frailty-context-modifier-map-v0.md) and [Molecular Immune Context Contract v0](contexts/molecular-immune-context-contract-v0.md). | High-risk, extramedullary, organ, bone, immune, molecular, cytogenetic, genomic, target-assay, pathology, flow, frailty, performance-status, and prior-exposure context labels are optional or source-scoped, non-identifying, and cannot produce actionability, test guidance, prognosis, eligibility, treatment, monitoring, trial fit, or option ranking. |
| Public translation and contribution | [Public Translation And Contribution Guide v0](public-translation-contribution-guide-v0.md), [CONTRIBUTING.md](../../CONTRIBUTING.md), and the source extraction, evidence gap, and expert review issue forms. | Non-specialists can find the right artifact within three links from the disease README, and contributors can choose a safe public task without creating advice, ranking, case intake, or publication authorization. |
| Review readiness | [BCMA Claim Set Expert Review Packet v0](reviews/bcma-claim-set-expert-review-packet-v0.md), [Multidisciplinary Review Packet Template v0](reviews/multidisciplinary-review-packet-template-v0.md), [Candidate Hypothesis Review Question Set v0](reviews/candidate-hypothesis-review-question-set-v0.md), [Multidisciplinary Review Packet Builder v0](reviews/multidisciplinary-review-packet-builder-v0.md), [Expert Validation Issue Index v0](reviews/expert-validation-issue-index-v0.md), [Expert Response Validation Ledger v0](reviews/expert-response-validation-ledger-v0.md), [Expert Validation Loop v0](reviews/expert-validation-loop-v0.md), [Expert Validation Outreach Map v0](reviews/expert-validation-outreach-map-v0.md), manifest specs, dry-run plans, packet-assembly gates, and recombination handoff. | Expert-review-needed; 13 public validation issues are opened and mapped to safe dispositions; outreach candidates are mapped; candidate hypotheses can now be represented only as source-scoped review questions; builder routing is limited to copy, reference, omit, or refuse; expert validation can recur only as public disposition plumbing; packet assembly remains blocked. |
| Schemas and tools | Disease-map, target, therapy, trial-landscape, open-question, review-packet manifest, route-table output, case-feature summary, case-feature normalization, measurement normalization, therapy exposure timeline, and molecular immune context contracts, plus the route-table dry-run tool. | Validated public tooling substrate; no generated clinical claims. |
| Source anchors | [Source Registry v0](../../sources/source-registry-v0.md), [ClinicalTrials.gov Query Protocol v0](../../protocols/clinicaltrials-gov-query-protocol-v0.md), and [Treatment-Class Taxonomy v0](../../taxonomies/multiple-myeloma-treatment-class-taxonomy-v0.md). | Reusable public provenance anchors; not proof of completeness. |

## Current Readiness

| Question | Current Answer |
| --- | --- |
| Is the public v0 artifact surface complete for the current autonomous loop? | Complete for the earlier public loop handoff, frontier lanes, and adaptive case-to-cure master backlog after [Case-To-Cure Master Completion Audit v0](case-to-cure-master-completion-audit-v0.md) is cataloged and validation passes. |
| Are there ready public tasks left in the current queues? | The public task listing reports zero ready issue tasks, and the ORP additional queue now blocks on `case-to-cure-public-scope-human-gate-blocker-v0` until a human selects a new named public-safe phase or clears a named gate. |
| Is the public surface ready for protected-branch review? | Yes, after validation and release-gate checks pass. |
| Is the science complete? | No. The repo keeps source scope, uncertainty, and limitations visible. |
| Are claims expert-reviewed? | No. Review packets still mark expert-review-needed items. |
| Are public expert-validation issues opened? | Yes. Issues [#22](https://github.com/SproutSeeds/curing-blood-cancer/issues/22) through [#34](https://github.com/SproutSeeds/curing-blood-cancer/issues/34) map to the current 13 review items. |
| Is there a public-safe response ledger? | Yes. [Expert Response Validation Ledger v0](reviews/expert-response-validation-ledger-v0.md) maps all 13 issues to `keep-expert-review-needed` and next public actions until safe public dispositions are reviewed. |
| Can MRD or complete-response language be reused as a cure claim? | No. [MRD Endpoint Language Guardrail Addendum v0](measurements/mrd-endpoint-language-guardrail-addendum-v0.md) requires source context and fail-closed wording before downstream use. |
| Can immune therapy product or trial references be read as access advice? | No. [Immune Therapy Sequencing And Access Boundary v0](therapy-landscapes/immune-therapy-sequencing-access-boundary-v0.md) requires date-stamped status fields and blocks availability, eligibility, sequencing, and ranking inferences. |
| Can post-BCMA resistance mechanisms be read as patient options? | No. [Post-BCMA Resistance Frontier Addendum v0](mechanisms/post-bcma-resistance-frontier-addendum-v0.md) labels mechanism families by claim level and blocks ranking, product comparison, trial inference, and patient-action use. |
| Can precursor-state or risk language be read as screening or personal risk advice? | No. [Precursor, Risk, And Interception Boundary Note v0](precursors/precursor-risk-interception-boundary-note-v0.md) blocks screening prompts, personal risk calculators, treatment recommendations, trial fit, monitoring schedules, and prevention claims. |
| Can high-risk, organ, frailty, or extramedullary context fields produce prognosis or option ranking? | No. [High-Risk, Extramedullary, Organ, And Frailty Context Modifier Map v0](contexts/high-risk-organ-frailty-context-modifier-map-v0.md) keeps context fields optional, source-scoped, non-identifying, and non-directive. |
| Does the case-to-cure dry run map every stage to an owner artifact, validator, and blocker? | Yes. [Case-To-Cure Stage Validator And Owner Map v0](case-to-cure-stage-validator-map-v0.md) maps `case_00` through `case_14` to public owner artifacts, validator or gate fields, blocked conditions, and allowed public successors. |
| Can non-specialists and contributors find the right safe public task? | Yes. [Public Translation And Contribution Guide v0](public-translation-contribution-guide-v0.md) maps reader goals to safe artifact paths and maps contribution needs to source extraction, evidence gap, expert review, wording, and metadata repair surfaces. |
| Is the frontier v0 autonomous loop complete? | Yes, after [Frontier Completion Audit Handoff v0](frontier-completion-audit-handoff-v0.md) is wired and validation passes. No new ready public task is selected without a new named phase gate. |
| What completed named phase gate created the intake foundation? | `case-intake-frontier-v0` is the caregiver case intake foundation, anchored by [Caregiver Case Intake Product Spec v0](case-intake/caregiver-case-intake-product-spec-v0.md), the [Caregiver Intake Public Projection Checklist v0](case-intake/caregiver-intake-public-projection-checklist-v0.md), the synthetic-only [Caregiver Intake Fixture v0](../../examples/multiple-myeloma-synthetic-caregiver-intake-v0.json), and the [Case Intake Frontier Completion Audit Handoff v0](case-intake/case-intake-frontier-completion-audit-handoff-v0.md). |
| What did the loop governor complete? | [Case-To-Cure Loop Governor Handoff v0](case-to-cure-loop-governor-handoff-v0.md) closes `case-to-cure-loop-governor-v0` and records why completed subphases should flow into the next public-safe queue item instead of stopping the master plan. |
| What did the private intake contract complete? | [Private Intake Schema Contract v0](case-intake/private-intake-schema-contract-v0.md) defines private-only field groups, unknown states, provenance fields, and public projection outcomes without a live schema, backend, upload path, or case record. |
| What did the static synthetic prototype complete? | [Static Synthetic Caregiver Prototype Plan v0](case-intake/static-synthetic-caregiver-prototype-plan-v0.md) maps all `intake_00` through `intake_11` screens, synthetic fixture bindings, refusal paths, required copy families, and fail-closed projection states without creating a public form, backend, upload path, or patient-specific output. |
| What did the public projection validator complete? | [Caregiver Intake Public Projection Validator v0](case-intake/caregiver-intake-public-projection-validator-v0.md) defines fail-closed protocol checks and synthetic test cases for PHI, real case content, free text, uploads, advice language, unknown-state inference, missing gates, and publication bypass without processing real data. |
| What did the consent/privacy/security/retention gate complete? | [Consent Privacy Security Retention Gate v0](case-intake/consent-privacy-security-retention-gate-v0.md) records the human and technical blockers before any real intake, storage, retention, emergency handling, clinician review, or case-derived public learning. |
| What did the case-feature normalization contract complete? | [Case Feature Normalization Contract v0](case-feature-normalization-contract-v0.md) defines the public-safe normalized feature envelope, value states, source status, timepoint buckets, review gates, limitations, and allowed public successors without creating a fillable real-case schema or interpretation path. |
| What did the measurement normalization contract complete? | [Measurement Normalization Contract v0](measurements/measurement-normalization-contract-v0.md) defines public-safe MRD, response, relapse, lab, imaging, endpoint, source, method, sample, threshold, timepoint, duration, review, and limitation fields without publishing real values or interpreting measurements for a person. |
| What did the therapy exposure timeline contract complete? | [Therapy Exposure Timeline Contract v0](therapy-landscapes/therapy-exposure-timeline-contract-v0.md) defines public-safe therapy class, exposure state, line or timing bucket, response linkage, toxicity or constraint category, refractory context, source status, review status, and limitation fields without publishing real therapy histories or sequencing, eligibility, access, monitoring, ranking, or treatment guidance. |
| What did the molecular immune context contract complete? | [Molecular Immune Context Contract v0](contexts/molecular-immune-context-contract-v0.md) defines public-safe cytogenetic, genomic, target-assay, pathology, flow, immune context, assay-validity, source-validity, therapy-linkage, measurement-linkage, review, uncertainty, and limitation fields without publishing real reports or actionability, testing, treatment, trial, monitoring, ranking, or patient-specific interpretation. |
| What did the evidence retrieval packet complete? | [Evidence Retrieval Packet v0](evidence-retrieval-packet-v0.md) defines a public-source-only packet skeleton for source IDs, query records, source freshness, access-date state, limitations, uncertainty, no-completeness warnings, review status, and no-advice boundaries without patient matching, trial matching, actionability, availability, eligibility, monitoring, ranking, or patient-specific interpretation. |
| What did the trial/therapy landscape non-advice gate complete? | [Trial Therapy Landscape Non-Advice Gate v0](therapy-landscapes/trial-therapy-landscape-non-advice-gate-v0.md) defines public-safe trial, therapy, product, target, jurisdiction, status, source freshness, access-date, uncertainty, limitation, and review fields without availability claims, eligibility claims, patient matching, trial matching, sequencing, access guidance, ranking, or patient-specific interpretation. |
| What did the candidate hypothesis review question set complete? | [Candidate Hypothesis Review Question Set v0](reviews/candidate-hypothesis-review-question-set-v0.md) defines source-scoped review questions for qualified humans with evidence packet IDs, landscape gate status, source context, uncertainty, review lens, blocked uses, and explicit no patient-action output, without candidate options, recommendations, rankings, matching, treatment guidance, trial guidance, expanded-access guidance, monitoring guidance, or patient-specific interpretation. |
| What did the multidisciplinary review packet builder complete? | [Multidisciplinary Review Packet Builder v0](reviews/multidisciplinary-review-packet-builder-v0.md) defines public route rules for question IDs, artifact IDs, source IDs, review lenses, missing-input blockers, refusals, and boundaries, limited to copy, reference, omit, or refuse behavior without packet assembly, generated biomedical prose, real case facts, patient-specific outputs, recommendations, rankings, matching, publication authorization, or clinical decisions. |
| What did the expert validation loop complete? | [Expert Validation Loop v0](reviews/expert-validation-loop-v0.md) defines public disposition-loop fields, allowed dispositions, fail-closed rules, synthetic tests, and next public actions for issue IDs, outreach-map roles, response-ledger states, source-context gaps, review lenses, uncertainty, and blocked uses without outreach, private correspondence, unpublished expert comments, recommendations, rankings, publication authorization, or clinical decisions. |
| What did the case-to-public learning extraction gate complete? | [Case-To-Public Learning Extraction Gate v0](case-to-public-learning-extraction-gate-v0.md) defines allowed output types, privacy decision state, de-identification basis, aggregation state, minimum-size state, single-case claim blockers, public source context, review-lens and disposition fields, uncertainty, limitations, blocked uses, and publication-gate routing before any private-case learning can become public. |
| What did the end-to-end synthetic case dry run complete? | [End-To-End Synthetic Case Dry Run v0](end-to-end-synthetic-case-dry-run-v0.md) connects synthetic caregiver intake through publication-gate refusal with success, omit, refusal, and blocker paths while blocking real case data, patient-specific outputs, matching, ranking, clinical guidance, and publication authorization. |
| What did the master completion audit complete? | [Case-To-Cure Master Completion Audit v0](case-to-cure-master-completion-audit-v0.md) audits the adaptive backlog, marks the current public-safe autonomous case-to-cure scope complete, and names remaining work as expert-review-needed, private-lab-needed, clinical-team-needed, legal-needed, regulatory-needed, publication-gate-needed, or human-review-needed. |
| What is the live adaptive phase now? | `case-to-cure-adaptive-master-plan-v0`, anchored by [Case-To-Cure Adaptive Master Plan v0](case-to-cure-adaptive-master-plan-v0.md), with ORP active phase `case-to-cure-public-scope-human-gate-blocker-v0` and durable additional queue `case-to-cure-master-backlog-v0`. |
| Why should Clawdad keep going after a small phase completes? | The adaptive master plan requires every completed step to inspect what changed, write or update a handoff, synthesize the next safest public step, and queue, activate, or block that step explicitly. |
| Is this a patient-care system? | No. It is public research infrastructure only. |
| Does this contain real case data? | No. The public lane uses synthetic examples and blocker registers. |
| Can it guide treatment, trial selection, monitoring, or expanded access? | No. Those uses remain explicitly blocked. |

## Most Useful Entry Points

Start here:

1. [Public Roadmap v0](public-roadmap-v0.md) for the initiative plan.
2. [Public Translation And Contribution Guide v0](public-translation-contribution-guide-v0.md)
   for safe non-specialist navigation and contribution-task selection.
3. [Frontier Completion Audit Handoff v0](frontier-completion-audit-handoff-v0.md)
   for the current autonomous frontier endpoint and residual blockers.
4. [Open Research Map v0.1](open-research-map-v0-1.md) for the first
   source-backed myeloma map.
5. [Case-To-Cure Pipeline Blueprint v0](case-to-cure-pipeline-blueprint-v0.md)
   for the public-safe pipeline shape.
6. [Case-To-Cure Adaptive Master Plan v0](case-to-cure-adaptive-master-plan-v0.md)
   for the durable loop that turns completed steps into next-step decisions.
7. [Case-To-Cure Loop Governor Handoff v0](case-to-cure-loop-governor-handoff-v0.md)
   for the active ORP queue update from loop governor to private-intake schema
   contract.
8. [Case-To-Cure Stage Validator And Owner Map v0](case-to-cure-stage-validator-map-v0.md)
   for stage owners, validator or gate fields, blockers, and allowed public successors.
9. [Caregiver Case Intake Product Spec v0](case-intake/caregiver-case-intake-product-spec-v0.md)
   for the completed caregiver intake subphase and private handoff boundary.
10. [Caregiver Intake Public Projection Checklist v0](case-intake/caregiver-intake-public-projection-checklist-v0.md)
   for fail-closed no-PHI, no-advice, unknown-state, final-review, clinician-review, privacy, and publication gates.
11. [Private Intake Schema Contract v0](case-intake/private-intake-schema-contract-v0.md)
   for private-only field groups, unknown states, provenance fields, and public
   projection outcomes.
12. [Static Synthetic Caregiver Prototype Plan v0](case-intake/static-synthetic-caregiver-prototype-plan-v0.md)
   for static synthetic screen planning, fixture binding, refusal paths, and
   public-submission blockers.
13. [Caregiver Intake Public Projection Validator v0](case-intake/caregiver-intake-public-projection-validator-v0.md)
   for fail-closed public projection checks and synthetic test cases.
14. [Consent Privacy Security Retention Gate v0](case-intake/consent-privacy-security-retention-gate-v0.md)
   for consent, privacy, security, retention, emergency, clinician-review, and publication blockers before real intake.
15. [Case Feature Normalization Contract v0](case-feature-normalization-contract-v0.md)
   for normalized feature groups, unknown states, provenance, timepoint buckets, review gates, and public-successor boundaries.
16. [Case Intake Frontier Completion Audit Handoff v0](case-intake/case-intake-frontier-completion-audit-handoff-v0.md)
   for the current public case-intake phase closure and residual blockers.
17. [Public Loop Completion Handoff v0](public-loop-completion-handoff-v0.md)
   for why the autonomous v0 loop stopped.
18. [Public Review And Release Gate v0](public-review-release-gate-v0.md) for
   release constraints.
19. [Public Review Release Gate Pass v0](public-review-release-gate-pass-v0.md)
   for the current PR-readiness pass.
20. [Expert Validation Issue Index v0](reviews/expert-validation-issue-index-v0.md)
   for the public expert-review request surface.
21. [Expert Response Validation Ledger v0](reviews/expert-response-validation-ledger-v0.md)
   for public-safe intake status and allowed dispositions.
22. [MRD Endpoint Language Guardrail Addendum v0](measurements/mrd-endpoint-language-guardrail-addendum-v0.md)
   for response-depth and endpoint wording boundaries.
23. [Measurement Normalization Contract v0](measurements/measurement-normalization-contract-v0.md)
   for MRD, response, relapse, lab, imaging, method, threshold, sample, timepoint, endpoint, and limitation fields.
24. [Therapy Exposure Timeline Contract v0](therapy-landscapes/therapy-exposure-timeline-contract-v0.md)
   for therapy class, exposure state, line or timing bucket, response linkage, toxicity or constraint category, refractory context, source status, and non-advisory boundaries.
25. [Molecular Immune Context Contract v0](contexts/molecular-immune-context-contract-v0.md)
   for cytogenetic, genomic, target-assay, pathology, flow, immune-context, assay-validity, source-validity, source-status, and actionability boundaries.
26. [Evidence Retrieval Packet v0](evidence-retrieval-packet-v0.md)
   for public-source IDs, query records, source freshness, access-date state, limitations, uncertainty, no-completeness warnings, and no-advice retrieval boundaries.
27. [Trial Therapy Landscape Non-Advice Gate v0](therapy-landscapes/trial-therapy-landscape-non-advice-gate-v0.md)
   for trial, therapy, product, target, jurisdiction, status, freshness, access-date, limitation, uncertainty, review, and non-advice landscape boundaries.
28. [Candidate Hypothesis Review Question Set v0](reviews/candidate-hypothesis-review-question-set-v0.md)
   for source-scoped candidate review questions, review lenses, blocked uses,
   uncertainty, and no patient-action output.
29. [Multidisciplinary Review Packet Builder v0](reviews/multidisciplinary-review-packet-builder-v0.md)
   for public route rules that copy, reference, omit, or refuse question,
   artifact, source, lens, blocker, refusal, and boundary fields.
30. [Expert Validation Loop v0](reviews/expert-validation-loop-v0.md)
   for public-safe expert validation dispositions, source-context tasks,
   review-lens gaps, uncertainty, blocked uses, and next public actions.
31. [Case-To-Public Learning Extraction Gate v0](case-to-public-learning-extraction-gate-v0.md)
   for allowed output types, privacy state, aggregation state, public source
   context, review dispositions, blocked uses, and publication-gate routing
   before any case-derived public learning.
32. [End-To-End Synthetic Case Dry Run v0](end-to-end-synthetic-case-dry-run-v0.md)
   for the synthetic route table that exercises success, omit, refusal, and
   blocker paths from caregiver intake through publication-gate refusal.
33. [Case-To-Cure Master Completion Audit v0](case-to-cure-master-completion-audit-v0.md)
   for the adaptive backlog completion audit and named human-gate blocker.
34. [Immune Therapy Sequencing And Access Boundary v0](therapy-landscapes/immune-therapy-sequencing-access-boundary-v0.md)
   for immune-therapy status freshness and access-boundary rules.
35. [Post-BCMA Resistance Frontier Addendum v0](mechanisms/post-bcma-resistance-frontier-addendum-v0.md)
   for mechanism claim levels, uncertainty, and contribution boundaries.
36. [Precursor, Risk, And Interception Boundary Note v0](precursors/precursor-risk-interception-boundary-note-v0.md)
   for MGUS, smoldering myeloma, risk, and early-intervention language boundaries.
37. [High-Risk, Extramedullary, Organ, And Frailty Context Modifier Map v0](contexts/high-risk-organ-frailty-context-modifier-map-v0.md)
   for optional, source-scoped context labels and review-packet checklist boundaries.
38. [Expert Validation Outreach Map v0](reviews/expert-validation-outreach-map-v0.md)
   for the public shortlist of people and reviewer lenses to contact.
39. [Public Artifact Catalog v0](../../artifacts/public-artifact-catalog-v0.md)
   for the full metadata-backed listing.

## What Comes Next

The active adaptive backlog is complete for the current public-safe
autonomous case-to-cure scope. Protected-branch or maintainer review is still
needed before release or publication. No new autonomous public-safe
case-to-cure item is ready until a human chooses a new named phase or clears a
named gate. Useful human-gated next phases include:

- human selection of a new named public-safe phase, if the project wants to
  extend beyond the audited case-to-cure backlog
- human review of the frontier completion handoff and protected-branch release
  readiness
- public-source-backed disposition updates from issues #22 through #34
- MRD endpoint source extraction from public FDA, IMWG, and MRD literature
  anchors
- immune-therapy product and trial status extraction into a validated
  non-advisory landscape record shape
- post-BCMA primary-study contradiction capture and measurement harmonization
  before any mechanism dashboard, comparison, or scoring work
- precursor-state definition extraction, risk-model context extraction, and
  early-intervention trial-language guardrails with no calculator or screening
  output
- context-modifier definition extraction, case-feature addendum drafting, and
  synthetic fixture coverage only after a schema lane selects optional
  non-identifying context fields
- case-to-cure structured graph or fixture expansion only after a bounded
  schema or tooling lane selects it and keeps public outputs synthetic or
  aggregate-only
- source-backed map expansion with a new gate and explicit source rules
- plain-language review of the public translation guide for patients,
  caregivers, and public contributors
- synthetic-only tooling checks that preserve no-ranking and no-advice
  boundaries
- private-lab handoffs outside this public repo when real case work is needed

## What This Is Not

This inventory is not:

- medical advice
- diagnosis, prognosis, treatment, trial, eligibility, monitoring, or
  expanded-access guidance
- a target, therapy, trial, source, mechanism, artifact, task, or evidence
  ranking
- expert review
- clinical review
- a claim that multiple myeloma has been cured
- a claim that any vaccine has been found
- authorization to process public case data
- authorization to publish case-derived learning

## Public Safety Check

- No patient-identifying data.
- No real case data.
- No private records.
- No credentials, paid APIs, account changes, or restricted datasets.
- No patient-specific diagnosis, prognosis, treatment, trial, expanded-access,
  monitoring, or candidate-option guidance.
- No target, therapy, trial, source, mechanism, artifact, task, or evidence
  ranking.
- No generated biomedical claims.
- No expert-review substitution.
- No publication authorization.
- No cure or vaccine claim.

## Limitations

- This inventory is a navigation artifact, not a scientific review.
- This inventory does not prove source coverage is comprehensive.
- This inventory does not grade evidence quality.
- This inventory does not make claims expert-reviewed.
- This inventory does not inspect private lab records or real case data.
- This inventory does not authorize generated claims, ranking,
  recommendation behavior, patient matching, trial matching, review-packet
  assembly, or publication workflow.
- This inventory does not provide medical advice, diagnostic guidance,
  treatment guidance, trial guidance, eligibility guidance, expanded-access
  guidance, monitoring guidance, or a cure claim.
